

Fostemsavir

Brian R. Wood, MD Associate Editor, National HIV Curriculum Associate Professor of Medicine Division of Allergy and Infectious Diseases University of Washington

Last Updated: July 12, 2022

National HIV Curriculum www.hiv.uw.edu





Dr. Wood has no financial conflicts of interest or disclosures.


Fostemsavir



Dose: 1 tablet twice daily with or without food




Fostemsavir



Fostemsavir is a prodrug of temsavir




Fostemsavir: Hydrolysis by Alkaline Phosphatase



Fostemsavir undergoes hydrolysis on the luminal surface of the small intestine brush border membranes




Temsavir (Active Drug)





HIV Entry Inhibitors Fostemsavir: Attachment Inhibitor



Fostemsavir

Indication

- Heavily treatment-experienced adults with multidrug-resistant HIV-1

Drug-drug interactions

- Avoid: strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's wort), grazoprevir, voxilaprevir, >30 mcg/day ethinyl estradiol
- Use with caution if prolonged QTc or taking meds known to cause torsade de pointes
- Consider statin dose adjustment (use lowest possible statin starting dose)

Use during pregnancy

- Insufficient data





Fostemsavir for Heavily Treatment-Experienced Individuals BRIGHTE Study (Week 48 Data)



Fostemsavir for Heavily Treatment-Experienced Individuals BRIGHTE Study (Week 48): Background


Background

 Phase 3, randomized, placebocontrolled, non-inferiority trial evaluating fostemsavir (FTR) in salvage ART

Enrollment Criteria:

- Highly ART-experienced adults
- Virologic failure on current ART
- HIV RNA >400 copies/mL
- Multiclass ART resistance
- At least one fully active agent (for randomized cohort)

*OBR = optimized background regimen





Source: Kozal M, et al. N Engl J Med. 2020;382:1232-43.

Fostemsavir for Heavily-Treatment Experienced Individuals BRIGHTE Study (Week 48): Baseline Characteristics

Baseline Characteristics	Randomized (n = 272)	Non-Randomized (n = 99)
Age, years, median (range)	48 (18-73)	50 (17-72)
Male sex, n (%)	200 (74)	89 (90)
White, n (%)	184 (68)	74 (74)
Black/African American, n (%)	60 (22)	23 (23)
HIV RNA 1,000-100,000 copies/mL, n (%)	161 (59)	75 (76)
HIV RNA >100,000 copies/mL, n (%)	80 (29)	15 (15)
CD4 count—cells/mm ³ , median (range)	99 (0-1160)	41 (0-641)
2 fully active agents in OBR*, %	42	0
1 fully active agent in OBR*, %	52	19
0 fully active agents in OBR*, %	6	81


*Most common ARV's in OBR: dolutegravir, boosted darunavir, tenofovir DF, etravirine, maraviroc, enfuvirtide, ibalizumab

Source: Kozal M, et al. N Engl J Med. 2020;382:1232-43.



Fostemsavir for Heavily Treatment-Experienced Individuals BRIGHTE Study (Week 48): Results


Baseline to Day 8 Change in HIV RNA Level (Randomized Cohort)





Fostemsavir for Heavily Treatment-Experienced Individuals BRIGHTE Study (Week 48): Results

Virologic Response Through Week 48 (HIV RNA <40 copies/mL)








Fostemsavir for Heavily Treatment-Experienced Individuals BRIGHTE Study (Week 96 Data)



Fostemsavir for Heavily Treatment-Experienced Individuals BRIGHTE Study (Week 96): Results

Virologic Response Through Week 96 (HIV RNA <40 copies/mL)






Source: Lataillade M, et al. Lancet HIV. 2020;7:e740-51.

Fostemsavir for Heavily Treatment-Experienced Individuals BRIGHTE Study (Week 96): Results

Mean Change in CD4 T-Cell Count Through Week 96





Source: Lataillade M, et al. Lancet HIV. 2020;7:e740-51.

Fostemsavir for Heavily Treatment-Experienced Individuals BRIGHTE Study (Week 96): Results

Adverse Events (AEs)	Randomized (n = 272)	Non-Randomized (n = 99)
Any AE, n (%)	249 (92)	98 (99)
Drug-related grade 2-4 AEs, n (%)	57 (21)	22 (22)
Nausea	9 (3)	5 (5)
Diarrhea	6 (2)	3 (3)
Headache	6 (2)	1 (1)
Vomiting	4 (1)	2 (2)
Fatigue	3 (1)	2 (2)
Asthenia	2 (<1)	2 (2)
Drug-related AE leading to discontinuation, n (%)	7 (3)	7 (3)
Drug-related serious AE, n (%)	9 (3)	3 (3)

Source: Lataillade M, et al. Lancet HIV. 2020;7:e740-51.





Fostemsavir Resistance



Fostemsavir for Heavily Treatment-Experienced Individuals BRIGHTE Study (Week 96): Virologic Failures

	Randomized (n = 272)	Non-Randomized (n = 99)
Number of virologic failures	69/272 (25%)	50/99 (51%)
With gp120 RAPs at screening (of those with genotypic data)	43/68 (63%)	26/48 (54%)
Virologic failures with post-baseline data	53	45
With emergent gp120 (<i>env</i>) RAS	29/53 (55%)	33/45 (73%)
S 375 H/I/M/N/T	19/53 (36%)	21/45 (47%)
M 426 L/I	18/53 (34%)	23/45 (51%)
M 434 I/L	6/53 (11%)	5/45 (11%)
M475I/L/V	8/53 (15%)	5/45 (11%)

Abbreviation: RAPs = Resistance-associated polymorphisms; RAS = Resistance-associated substitutions



Fostemsavir (FTR): Resistance Testing & Cross Resistance

- FTR can be used regardless of HIV-1 tropism
- Standard genotype testing does not give FTR resistance information
- Certain viral subtypes, such as AE, may have reduced susceptibility, but are rare
- HIV with resistance mutations in the gp120 envelope subunit due to virologic failure on ibalizumab or maraviroc may have reduced susceptibility to FTR, but are rare
- Viruses resistant to the gp41 inhibitor enfuvirtide typically retain susceptibility to FTR
- Other entry inhibitors tend to retain activity in the presence of FTR resistance mutations



Fostemsavir: Summary

- Oral, twice-daily, CD4 attachment inhibitor
- Typically used as part of salvage antiretroviral therapy for heavily-treatment experienced individuals
- Can be combined with other entry inhibitors (ibalizumab, enfuvirtide, maraviroc if R5-tropic), other salvage antiretrovirals, and/or optimized background regimen
- Overall, well tolerated with few drug-drug interactions, though need to consider interactions with strong CYP3A4 inducers, estradiol, statins, and drugs that may prolong the QTc or cause torsade de pointes
- Resistance mutations in the gp120 envelope subunit may develop with virologic failure



Acknowledgments

The production of this **National HIV Curriculum** Mini-Lecture was supported by Grant U1OHA32104 from the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS). Its contents are solely the responsibility of University of Washington IDEA Program and do not necessarily represent the official views of HRSA or HHS.





